Shenzhen Neptunus Interlong Bio technique Co Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shenzhen Neptunus Interlong Bio technique Co Ltd with three other
companies in this sector in China:
Ginwa Enterprise Group Inc.
sales of 727.82 million Chinese Renmimbi [US$105.47 million]
of which 52%
was Pharmaceutical Industry),
Autobio Diagnostics Co Ltd
(716.48 million Chinese Renmimbi [US$103.83 million]
Shanghai Fudan Forward S&T Co Ltd
(715.69 million Chinese Renmimbi [US$103.71 million]
of which 59%
During the year ended December of 2015, sales at
Shenzhen Neptunus Interlong Bio technique Co Ltd were 721.35 million Chinese Renmimbi (US$104.53 million).
increase of 11.3%
versus 2014, when the company's sales were 648.27 million Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Shenzhen Neptunus Interlong Bio technique Co Ltd
(and since 2010, sales have increased a total of 1,786%).
Sales of Purchase and Sales of Medicines and Health saw an increase
that was more than double the company's growth rate: sales were up
93.1% in 2015, from
137.18 million Chinese Renmimbi to 264.85 million Chinese Renmimbi.
Not all segments of Shenzhen Neptunus Interlong Bio technique Co Ltd experienced an increase in sales in 2015:
sales of Research and Development Services fell 94.3% to 63,000.00 Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Shenzhen Neptunus Interlong Bio technique Co Ltd also experienced decreases in sales in
Manufacturing and Selling Medicine Products (down 10.5% to 456.43 million Chinese Renmimbi)